# Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients

> **NCT02117518** · — · UNKNOWN · sponsor: **Migal Galilee Research Institute** · enrollment: 50 (estimated)

## Conditions studied

- Type I Diabetes

## Interventions

- **OTHER:** blood drawing

## Key facts

- **NCT ID:** NCT02117518
- **Lead sponsor:** Migal Galilee Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117518, "Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02117518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*